𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutations in the BRCA1 gene in Japanese breast cancer patients

✍ Scribed by Toyomasa Katagiri; Mitsuru Emi; Isao Ito; Kanji Kobayashi; Masataka Yoshimoto; Takuji Iwase; Fujio Kasumi; Yoshio Miki; Mark H. Skolnick; Yusuke Nakamura


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
519 KB
Volume
7
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis


Predisposing germline mutations in the BRCAl gene were identified recently in families with 17qlinked breast and ovarian cancers. Using single-strand conformation polymorphism (SSCP) analysis, we examined primary breast cancers for mutations in coding exons of BRCAl in a panel of 103 patients, of whom all either represented early-onset cases (<35 of age), were members of multiplyaffected families, and/or had developed bilateral breast cancers. Mutations were detected in tumors from four patients, all of whom had developed breast cancers bilaterally: a frame-shift due to a 2-bp deletion at codon 797; a nonsense mutation at codon 1214; and two missense mutations, one at codon 27 1 leading to Val + Met substitution, and the other at codon 1150 leading to Pro --* Ser substitution. In each case the same mutation was present in constitutional DNA. The mean age of onset was 49 years among the Japanese carriers of BRCAl mutations identified in this study, in contrast to the mean age of 35 observed among carriers of BRCAl mutations in a similar U.S. study (Futreal et al., 1994). The evidence reported here supports a rather limited role of BRCAl in breast carcinogenesis.


πŸ“œ SIMILAR VOLUMES


Germline mutations in the BRCA1 and BRCA
✍ A. Esra ManguoΗ§lu; GΓΌven LΓΌleci; Tayfun Γ–zΓ§elik; Taner Γ‡olak; Hagit Schayek; Mus πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 47 KB πŸ‘ 2 views

In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w

Founder mutation in the BRCA1 gene in Ma
✍ Ann S.G. Lee; G.H. Ho; P.C. Oh; C. Balram; L.L. Ooi; D.T.H. Lim; C.Y. Wong; G.S. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 48 KB πŸ‘ 1 views

The mutation spectrum of the BRCA1 gene among ethnic groups from Asia has not been well studied. We investigated the frequency of mutations in the BRCA1 gene among Malay breast cancer patients from Singapore, independent of family history. By using the protein truncation test (PTT) and direct sequen

BRCA2 gene mutations in Greek patients w
✍ Athanasios Armakolas; Angela Ladopoulou; Irene Konstantopoulou; B. Pararas; Ilia πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 37 KB πŸ‘ 2 views

Family history is a well-recognized risk factor for the development of breast cancer. The isolation of BRCA1 and BRCA2 genes, the two major predisposing genes in familial and to early onset breast and ovarian cancer, has resulted to the identification of a large number of families with mutations in

BRCA2 germline mutations in Japanese bre
✍ Rie Inoue; Toshikazu Ushijima; Takashi Fukutomi; Atsuo Fukami; Haruhiko Sugimura πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 125 KB πŸ‘ 2 views

Germline mutations of BRCA2 were examined in 20 Japanese breast cancer families without BRCA1 mutations, including one demonstrating cancer development in a male. Three different mutations, resulting in truncation of the BRCA2 protein, were detected in 3 different families. They were 9474insA (exon

BRCA1 gene in breast cancer
✍ Eliot M. Rosen; Saijun Fan; Richard G. Pestell; Itzhak D. Goldberg πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 312 KB πŸ‘ 1 views

## Abstract The __BRCA1__ gene was identified and cloned in 1994 based its linkage to early onset breast cancer and breast‐ovarian cancer syndromes in women. While inherited mutations of BRCA1 are responsible for about 40–45% of hereditary breast cancers, these mutations account for only 2‐3% of al